These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 27207330

  • 21. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
    Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR.
    J Crohns Colitis; 2018 May 25; 12(6):653-661. PubMed ID: 29385469
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E, Kabakchiev B, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS.
    J Crohns Colitis; 2016 May 25; 10(5):510-5. PubMed ID: 26783345
    [Abstract] [Full Text] [Related]

  • 25. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.
    Gut; 2007 Sep 25; 56(9):1232-9. PubMed ID: 17299059
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab.
    Bodini G, Savarino V, Peyrin-Biroulet L, de Cassan C, Dulbecco P, Baldissarro I, Fazio V, Giambruno E, Savarino E.
    Dig Liver Dis; 2014 Nov 25; 46(11):1043-6. PubMed ID: 25169962
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
    Paul S, Williet N, Nancey S, Veyrard P, Boschetti G, Phelip JM, Flourie B, Roblin X.
    Dig Dis Sci; 2021 Aug 25; 66(8):2744-2749. PubMed ID: 32936345
    [Abstract] [Full Text] [Related]

  • 30. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C, Beaugerie L, Pariente B, Seksik P, Amiot A, Abitbol V, Allez M, Cosnes J, Sokol H.
    J Crohns Colitis; 2015 Apr 25; 9(4):349-55. PubMed ID: 25547977
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.
    Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, Karmiris K, Ferrante M, Gils A, Vermeire S.
    Gut; 2016 Jul 25; 65(7):1126-31. PubMed ID: 25862647
    [Abstract] [Full Text] [Related]

  • 35. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J.
    Arch Dis Child; 2019 Mar 25; 104(3):246-250. PubMed ID: 30026253
    [Abstract] [Full Text] [Related]

  • 36. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X.
    J Crohns Colitis; 2016 May 25; 10(5):516-24. PubMed ID: 26802084
    [Abstract] [Full Text] [Related]

  • 37. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 25; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, Rosh JR, Ruemmele FM, Awni WM.
    Inflamm Bowel Dis; 2015 Apr 25; 21(4):783-92. PubMed ID: 25723614
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.